Uppsala, Sweden – 7 May 2019
Beactica AB, the Swedish drug discovery company, today announced that it has been selected to present at the 20th Annual BioEquity Europe 2019. The conference will take place on 20–21 May in Barcelona, Spain.
Dr Per Källblad, Chief Executive Officer, to present on Monday 20 May 2019 at 2:20 PM. The location is the Crowne Plaza Barcelona Fira Center, Room Vivaldi 1, and the session category is Next Wave.
Beactica’s presentation will cover key pipeline and corporate developments as well as plans for advancing its lead asset into preclinical development – This asset is an allosteric modulator of LSD1 that has shown promising preclinical in vivo results in several oncology indications, including glioblastoma. Representatives of the Company will also participate in one-to-one partnering meetings with potential investors.
Organised by Biocentury and EBD Group, BioEquity Europe is the most important biopharmaceutical investor conference in Europe. It is the seminal industry event for financial dealmakers looking for investor-validated life science companies positioning themselves to attract capital, and for pharmaceutical licensing professionals to assess top prospects.
Beactica AB is a specialist drug discovery company, utilising its proprietary methodologies to evaluate the interactions of molecules in order to generate novel therapeutics. As well as progressing its own drug discovery programmes in areas of unmet medical need, Beactica offers partnerships for fragment-based lead generation using its proprietary discovery platform. Founded in 2006 based on research carried out at Uppsala University, Beactica has established a reputation as a world-leader in fragment-based drug discovery using SPR biosensor technology. For more information on Beactica, please visit www.beactica.com.
Sign up for the Beactica newsletter to receive our latest news and updates